Diagnostic utility of FGF-23 in mineral bone disorder during chronic kidney disease

Our data confirm that intact fibroblast growth factor 23 (iFGF-23) concentration is increased in patients with chronic kidney disease (CKD) and that it increases with disease progression (stages I-V). Therefore, iFGF-23 could be considered an early biomarker in the course of chronic kidney disease-m...

Descripción completa

Detalles Bibliográficos
Autores principales: Albanese, Luisa, Caliendo, Gemma, D’Elia, Giovanna, Passariello, Luana, Molinari, Anna Maria, Napoli, Claudio, Vietri, Maria Teresa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AboutScience 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8749389/
https://www.ncbi.nlm.nih.gov/pubmed/35023876
http://dx.doi.org/10.33393/jcb.2022.2328

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8749389/
https://www.ncbi.nlm.nih.gov/pubmed/35023876
http://dx.doi.org/10.33393/jcb.2022.2328

Ejemplares similares